GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT07444073

Not yet recruiting

Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock

Lead sponsor

National University of Singapore

Assets

GLP-1 / incretin class catch-all / Semaglutide / Tirzepatide

Listed sites

Recruiting sites

—

Enrollment

440

estimated

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥27.5

Primary endpoint

•LinAge2 Biological Age

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07444073

Org study IDNUS-IRB-2025-845

Timeline

Milestones

Study start2026-02-02estimated

Study first posted2026-03-02actual

Last update posted2026-03-02actual

Primary completion2026-12-31estimated

Study completion2026-12-31estimated

Assets

Investigational agents

GLP-1 / incretin class catch-all Semaglutide Tirzepatide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age40 Years

Maximum age89 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

Adults aged 40-89 years who are overweight or obese and newly enrolled in the NOVI Health weight management program in Singapore. Participants are selected from routine clinical practice at the NOVI Health clinic.

Inclusion criteria

•Adults aged 40-89 years, who are newly enrolled in the NOVI OP+ weight management program.

•BMI of ≥ 27.5 kg/m2 (if Asian) or 30 kg/m2 (if non-Asian); OR

•BMI of ≥ 23 kg/m2 (if Asian) / 25 (if non-Asian) kg/m2 in the presence of a weight-related chronic condition (e.g., diabetes, pre-diabetes, polycystic ovarian syndrome, hypertension, fatty liver, high cholesterol).

Exclusion criteria

•Pregnancy or lactation.

•Non-ambulatory status, total blindness, complete hearing loss, or inability to speak.

•Medical history of, or self-reported, psychiatric illness, congenital or irreversible neurodegenerative diseases, cognitive impairment, or eating disorders that may affect adherence or assessment outcomes.

•Concomitant anti-diabetic therapy.

•Active cancer on chemotherapy or immunotherapy.

•Known hypersensitivity or contraindications to GLP-1 RAs.

•Any condition, in the opinion of the attending clinician, that would jeopardize participant safety or interfere with study compliance.

Endpoints (31)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Other clinical outcomes

Cardiometabolic biomarkers

Renal / kidney

Glycemic / diabetes

MASH / liver

Patient-reported / QoL

Other (unclassified)

Weight & body composition

9 endpoints

Secondary/protocol endpoint

Change in Body Composition: Body Weight

Time frame:Baseline and 6 months

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change in Body Composition: Body Mass Index (BMI)

Time frame:Baseline and 6 months

BMI, change

change from baseline, improvement

Secondary/protocol endpoint

Change in Body Composition: Waist Circumference

Time frame:Baseline and 6 months

Waist circumference, change

change from baseline, improvement

Secondary/protocol endpoint

Change in Body Composition: Hip Circumference

Time frame:Baseline and 6 months

change from baseline, improvement

Secondary/protocol endpoint

Change in Body Composition: Waist-to-Hip Ratio

Time frame:Baseline and 6 months

ratio, improvement

Secondary/protocol endpoint

Change in Body Composition: Body Fat Percentage

Time frame:Baseline and 6 months

Total fat mass

change from baseline, improvement

Secondary/protocol endpoint

Change in Body Composition: Muscle Mass

Time frame:Baseline and 6 months

Lean mass

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in Body Composition: Basal Metabolic Rate

Time frame:Baseline and 6 months

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Change in Body Composition: Metabolic Age

Time frame:Baseline and 6 months

change from baseline, improvement

Glycemic / diabetes

2 endpoints

Secondary/protocol endpoint

Change in Cardiometabolic: Glycohemoglobin (HbA1c)

Time frame:Baseline and 6 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in Cardiometabolic: Glucose

Time frame:Baseline and 6 months

change from baseline, improvement

MASH / liver

2 endpoints

Secondary/protocol endpoint

Change in Hepatic: Alanine Aminotransferase (ALT)

Time frame:Baseline and 6 months

ALT, change

change from baseline, improvement

LOINC 1742-6

Secondary/protocol endpoint

Change in Hepatic: Aspartate Aminotransferase (AST)

Time frame:Baseline and 6 months

AST, change

change from baseline, improvement

LOINC 1920-8

Renal / kidney

3 endpoints

Secondary/protocol endpoint

Change in Renal: Serum Creatinine

Time frame:Baseline and 6 months

change from baseline, improvement

Secondary/protocol endpoint

Change in Renal: Blood Urea Nitrogen

Time frame:Baseline and 6 months

change from baseline, improvement

Secondary/protocol endpoint

Change in Renal: Urine Albumin

Time frame:Baseline and 6 months

change from baseline, improvement

Cardiometabolic biomarkers

6 endpoints

Secondary/protocol endpoint

Change in Pulse Rate

Time frame:Baseline and 6 months

Heart rate, change

change from baseline, improvement

Secondary/protocol endpoint

Change in Blood Pressure

Time frame:Baseline and 6 months

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Change in Cardiometabolic: Total Cholesterol

Time frame:Baseline and 6 months

Total cholesterol, change

change from baseline, improvement

LOINC 2093-3

Secondary/protocol endpoint

Change in Cardiometabolic: High-Density Lipoprotein (HDL) Cholesterol

Time frame:Baseline and 6 months

HDL-C, change

change from baseline, improvement

LOINC 2085-9

Secondary/protocol endpoint

Change in Cardiometabolic: Triglycerides

Time frame:Baseline and 6 months

Triglycerides, change

change from baseline, improvement

LOINC 2571-8

Secondary/protocol endpoint

Change in Cardiometabolic: C-Reactive Protein (CRP)

Time frame:Baseline and 6 months

hs-CRP, change

change from baseline, improvement

LOINC 30522-7

Patient-reported / QoL

1 endpoint

Secondary/protocol endpoint

Questionnaire: Self-reported health

Time frame:Baseline and 6 months

descriptive, improvement

Other clinical outcomes

7 endpoints

Secondary/protocol endpoint

Change in Functional Clinical Measures: Handgrip Strength (Southampton protocol)

Time frame:Baseline and 6 months

change from baseline, improvement

Secondary/protocol endpoint

Change in Functional Clinical Measures: Change in Chester Step Test Estimated VO₂max

Time frame:Baseline and 6 months

change from baseline, improvement

Secondary/protocol endpoint

Change in Functional Clinical Measures: Change in Five-Times Sit-to-Stand Test Time

Time frame:Baseline and 6 months

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Questionnaire: PAR-Q Physical Activity Readiness Questionnaire

Time frame:Baseline and 6 months

descriptive

Secondary/protocol endpoint

Questionnaire: Smoking status

Time frame:Baseline and 6 months

categorical status, descriptive

Secondary/protocol endpoint

Questionnaire: Co-morbidity index (22 conditions)

Time frame:Baseline

descriptive

Secondary/protocol endpoint

Questionnaire: Healthcare use index

Time frame:Baseline

event count, descriptive

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

LinAge2 Biological Age

Time frame:Baseline and 6 months

change from baseline, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Principal component-based clinical aging clocks identify signatures of healthy aging and targets for clinical intervention.
Nature aging2024 Aug (month)PMID38898237doi:10.1038/s43587-024-00646-8via CT.gov background

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.